Beatrice Waser1, Jean Claude Reubi. 1. Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, PO Box 62, Murtenstrasse 31, 3010 Bern, Switzerland.
Abstract
PURPOSE: Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients. Moreover, it was recently reported that antagonist tracers were superior to agonist tracers for somatostatin and gastrin-releasing peptide receptor targeting of tumours. The present preclinical study determines therefore the value of an established GLP-1 receptor antagonist for the in vitro visualization of GLP-1 receptor-expressing tissues in mice and humans. METHODS: Receptor autoradiography studies with (125)I-GLP-1(7-36)amide agonist or (125)I-Bolton-Hunter-exendin(9-39) antagonist radioligands were performed in mice pancreas and insulinomas as well as in human insulinomas; competition experiments were performed in the presence of increasing concentration of GLP-1(7-36)amide or exendin(9-39). RESULTS: The antagonist (125)I-Bolton-Hunter-exendin(9-39) labels mouse pancreatic β-cells and mouse insulinomas, but it does not label human pancreatic β-cells and insulinomas. High affinity displacement (IC(50) approximately 2 nM) is observed in mouse β-cells and insulinomas with either the exendin(9-39) antagonist or GLP-1(7-36)amide agonist. For comparison, the agonist (125)I-GLP-1(7-36)amide intensively labels mouse pancreatic β-cells, mouse insulinoma and human insulinomas; high affinity displacement is observed for the GLP-1(7-36)amide in all tissues; however, a 5 and 20 times lower affinity is found for exendin(9-39) in the mouse and human tissues, respectively. CONCLUSION: This study reports a species-dependent behaviour of the GLP-1 receptor antagonist exendin(9-39) that can optimally target GLP-1 receptors in mice but not in human tissue. Due to its overly low binding affinity, this antagonist is an inadequate targeting agent for human GLP-1 receptor-expressing tissues, as opposed to the GLP-1 receptor agonist, GLP-1(7-36)amide.
PURPOSE: Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients. Moreover, it was recently reported that antagonist tracers were superior to agonist tracers for somatostatin and gastrin-releasing peptide receptor targeting of tumours. The present preclinical study determines therefore the value of an established GLP-1 receptor antagonist for the in vitro visualization of GLP-1 receptor-expressing tissues in mice and humans. METHODS: Receptor autoradiography studies with (125)I-GLP-1(7-36)amide agonist or (125)I-Bolton-Hunter-exendin(9-39) antagonist radioligands were performed in micepancreas and insulinomas as well as in humaninsulinomas; competition experiments were performed in the presence of increasing concentration of GLP-1(7-36)amide or exendin(9-39). RESULTS: The antagonist (125)I-Bolton-Hunter-exendin(9-39) labels mouse pancreatic β-cells and mouseinsulinomas, but it does not label human pancreatic β-cells and insulinomas. High affinity displacement (IC(50) approximately 2 nM) is observed in mouse β-cells and insulinomas with either the exendin(9-39) antagonist or GLP-1(7-36)amide agonist. For comparison, the agonist (125)I-GLP-1(7-36)amide intensively labels mouse pancreatic β-cells, mouseinsulinoma and humaninsulinomas; high affinity displacement is observed for the GLP-1(7-36)amide in all tissues; however, a 5 and 20 times lower affinity is found for exendin(9-39) in the mouse and human tissues, respectively. CONCLUSION: This study reports a species-dependent behaviour of the GLP-1 receptor antagonist exendin(9-39) that can optimally target GLP-1 receptors in mice but not in human tissue. Due to its overly low binding affinity, this antagonist is an inadequate targeting agent for humanGLP-1 receptor-expressing tissues, as opposed to the GLP-1 receptor agonist, GLP-1(7-36)amide.
Authors: Mihaela Ginj; Hanwen Zhang; Beatrice Waser; Renzo Cescato; Damian Wild; Xuejuan Wang; Judit Erchegyi; Jean Rivier; Helmut R Mäcke; Jean Claude Reubi Journal: Proc Natl Acad Sci U S A Date: 2006-10-20 Impact factor: 11.205
Authors: Andreas Wicki; Damian Wild; Daniel Storch; Christian Seemayer; Martin Gotthardt; Martin Behe; Stefan Kneifel; Michael J Mihatsch; Jean-Claude Reubi; Helmut R Mäcke; Gerhard Christofori Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Maarten Brom; Lieke Joosten; Wim J G Oyen; Martin Gotthardt; Otto C Boerman Journal: Contrast Media Mol Imaging Date: 2012 Mar-Apr Impact factor: 3.161
Authors: Tom J P Jansen; Sanne A M van Lith; Marti Boss; Maarten Brom; Lieke Joosten; Martin Béhé; Mijke Buitinga; Martin Gotthardt Journal: J Labelled Comp Radiopharm Date: 2019-08 Impact factor: 1.921
Authors: Pierre Larraufie; Geoffrey P Roberts; Anne K McGavigan; Richard G Kay; Joyce Li; Andrew Leiter; Audrey Melvin; Emma K Biggs; Peter Ravn; Kathleen Davy; David C Hornigold; Giles S H Yeo; Richard H Hardwick; Frank Reimann; Fiona M Gribble Journal: Cell Rep Date: 2019-02-05 Impact factor: 9.423
Authors: Steven E Kahn; Yi-Chun Chen; Nathalie Esser; Austin J Taylor; Daniël H van Raalte; Sakeneh Zraika; C Bruce Verchere Journal: Endocr Rev Date: 2021-09-28 Impact factor: 25.261